CD28 and neoplasm: In CAR-T cells, GITR co-stimulation yielded a comparable or even more robust anti-tumor activity than CD28 or 4-1BB G2 EGFR-targeted CAR-T cells in various tumor cell lines, including SKOV-3, A1847, and BxPC3 [127].